National Heart, Lung, and Blood Institute (NHLBI) clinical trial pipeline

6 trials changed in the last 30 days: 0 stopped, 3 with notable changes, 3 with minor changes only.

1. Notable

   Sirolimus (Rapamune ) for Relapse Prevention · Severe Aplastic…Sirolimus (Rapamune ) for Relapse Prevention · Severe Aplastic Anemia Responsive to Immunosuppressive Therapy

   Primary endpoint(s) modified

   Also in this update: Results posted: Oct 6, 2026

   National Heart, Lung, and Blood Institute (NHLBI)·Phase 2· NCT02979873· Registry history of NCT02979873 on ClinicalTrials.gov (opens the registry)

   Updated Oct 6, 2026

2. Notable

   Eltrombopag for Fanconi Anemia

   Primary endpoint(s) modified

   Also in this update: Results posted: Sep 16, 2026

   National Heart, Lung, and Blood Institute (NHLBI)·Phase 2· NCT03206086· Registry history of NCT03206086 on ClinicalTrials.gov (opens the registry)

   Updated Sep 16, 2026

3. Notable

   Escalating Doses of Fostamatinib · Stable Sickle Cell Disease

   Primary endpoint(s) modified

   Also in this update: Enrollment increased: 25 → 35 participants; Trial arms changed: 1 → 2

   National Heart, Lung, and Blood Institute (NHLBI)·Phase 1· NCT05904093· Registry history of NCT05904093 on ClinicalTrials.gov (opens the registry)

   Updated Sep 17, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.